Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,650 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: tada h. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: tada h. Jpn J Clin Oncol. 2018 Sep 1;48(9):855-859. doi: 10.1093/jjco/hyy097. Jpn J Clin Oncol. 2018. PMID: 30020510 Clinical Trial.
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Yamashita T, et al. Among authors: tada h. Trials. 2020 May 7;21(1):391. doi: 10.1186/s13063-020-04341-y. Trials. 2020. PMID: 32381018 Free PMC article. Clinical Trial.
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Yamashita T, et al. Among authors: tada h. Trials. 2020 Jun 8;21(1):503. doi: 10.1186/s13063-020-04408-w. Trials. 2020. PMID: 32513251 Free PMC article.
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Watanabe K, Niikura N, Kikawa Y, Oba M, Kobayashi K, Tada H, Ozaki S, Toh U, Yamamoto Y, Tsuneizumi M, Okuno T, Iwakuma N, Takeshita T, Iwamoto T, Ishiguro H, Masuda N, Saji S. Watanabe K, et al. Among authors: tada h. Breast Cancer Res Treat. 2023 Jun;199(2):253-263. doi: 10.1007/s10549-023-06911-5. Epub 2023 Mar 31. Breast Cancer Res Treat. 2023. PMID: 37000345 Free PMC article.
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S. Iwamoto T, et al. Among authors: tada h. Breast Cancer Res Treat. 2024 Jan;203(2):225-234. doi: 10.1007/s10549-023-07144-2. Epub 2023 Oct 25. Breast Cancer Res Treat. 2024. PMID: 37875670
Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma.
Nakagawa S, Miyashita M, Maeda I, Goda A, Tada H, Amari M, Kojima Y, Tsugawa K, Ohi Y, Sagara Y, Sato M, Ebata A, Harada-Shoji N, Suzuki T, Nakanishi M, Ohta T, Ishida T. Nakagawa S, et al. Among authors: tada h. Breast Cancer Res Treat. 2024 Apr;204(3):453-463. doi: 10.1007/s10549-023-07209-2. Epub 2024 Jan 5. Breast Cancer Res Treat. 2024. PMID: 38180699 Free PMC article.
1,650 results